Special Research Initiatives - Grant ID: SR0354474
Funder
Australian Research Council
Funding Amount
$30,000.00
Summary
Metals in Medicine. Metal-based drugs account for several billion dollars of pharmaceutical sales worldwide, but proportionally much less research and development has focussed on this area than organic drugs. Australia has played a pivotal role in the early development of metal-based pharmaceuticals, which remains a research strength. The dual aims of the initiative are to provide a network for a vibrant industry based around metals in medicine and to improve the health of Australians. The ini ....Metals in Medicine. Metal-based drugs account for several billion dollars of pharmaceutical sales worldwide, but proportionally much less research and development has focussed on this area than organic drugs. Australia has played a pivotal role in the early development of metal-based pharmaceuticals, which remains a research strength. The dual aims of the initiative are to provide a network for a vibrant industry based around metals in medicine and to improve the health of Australians. The initiative will foster national and international cross-disciplinary collaborations to address the impediments holding back Australia's potential to take full advantage of our research strength in metals in medicine.Read moreRead less
Coupling biophotonic modalities with machine based recognition systems for disease diagnosis. This project will develop new ways to diagnose canine cancer, malaria and atherosclerosis using infrared-based technology and sophisticated pattern recognition techniques in the hope to discover infrared biomarkers that will lead to early diagnosis of the disease and ultimately save lives.
Copper Radiopharmaceuticals for Molecular Imaging of Alzheimer's Disease. The expected outcome of this research is to develop molecular agents to allow non-invasive diagnostic imaging of senile plaques associated with the onset of Alzheimer's disease. This will contribute to a better understanding of the disease, assist in early diagnosis and help assess new intervention strategies. Alzheimer's disease is the most common form of dementia and affects over 160,000 Australians. The imaging agent ma ....Copper Radiopharmaceuticals for Molecular Imaging of Alzheimer's Disease. The expected outcome of this research is to develop molecular agents to allow non-invasive diagnostic imaging of senile plaques associated with the onset of Alzheimer's disease. This will contribute to a better understanding of the disease, assist in early diagnosis and help assess new intervention strategies. Alzheimer's disease is the most common form of dementia and affects over 160,000 Australians. The imaging agent market is a niche biotechnology industry in which Australia already has an international presence. The proposed research will lead to innovations to ensure Australia remains internationally competitive in this area. This research has potential social and economic benefits for the nation.Read moreRead less
Many cancers shed small amounts of DNA (circulating tumour DNA or ctDNA) into the patient’s bloodstream. Recent technological advances now allow levels of ctDNA to be accurately measured in the blood. Changes in ctDNA levels have potential to be used as specific markers of disease progression and/or response to cancer therapy. This research will advance the use of ctDNA to serially follow patients and individualise treatment decisions in cancer management across several cancer types.
Development and Testing of Novel Contrast Agents for Diagnostic Imaging. Demand for diagnostic imaging in the Australian healthcare system is growing at over 5% per annum. To facilitate imaging, Australia imports radiographic contrast media costing in excess of $50 million every year. Existing iodine-based agents are not ideal for X-ray absorption in current CT scanners and also cause moderate to severe allergic reaction in around 5% of all patients, sometimes with fatal results. New radiograph ....Development and Testing of Novel Contrast Agents for Diagnostic Imaging. Demand for diagnostic imaging in the Australian healthcare system is growing at over 5% per annum. To facilitate imaging, Australia imports radiographic contrast media costing in excess of $50 million every year. Existing iodine-based agents are not ideal for X-ray absorption in current CT scanners and also cause moderate to severe allergic reaction in around 5% of all patients, sometimes with fatal results. New radiographic media, which give enhanced contrast and provide greater patient comfort and safety are essential. Even a small fraction of the international market would generate millions of dollars in income, support growth and expertise in Imaging Technologies, and provide new markets for Australian mining of rare earth and bismuth metals.Read moreRead less
'Multi-Coloured' Tracers for Magnetic Particle Imaging . Magnetic Particle Imaging (MPI) is predicted to be the future of imaging and will outperform all current imaging techniques by having 'colours', improved resolution and 3D precision. This project aims to create 'multi-coloured' high-performance MPI tracers by synthesising a range of the most effective magnetic nanoparticle structures. The expected outcome is the fundamental understanding of the relationships between nanoparticle structures ....'Multi-Coloured' Tracers for Magnetic Particle Imaging . Magnetic Particle Imaging (MPI) is predicted to be the future of imaging and will outperform all current imaging techniques by having 'colours', improved resolution and 3D precision. This project aims to create 'multi-coloured' high-performance MPI tracers by synthesising a range of the most effective magnetic nanoparticle structures. The expected outcome is the fundamental understanding of the relationships between nanoparticle structures and their magnetic properties for the formation of MPI signals with distinct ‘colours’. The benefits will be a library of MPI tracers that are able to provide ‘coloured’, high intensity, precise signals beyond what can be achieved with other imaging technologies.Read moreRead less
Discovering New Biomarkers In Hepatocellular Carcinoma
Funder
National Health and Medical Research Council
Funding Amount
$122,714.00
Summary
Liver cancer is a leading cause of cancer death with increasing rates and a high mortality. The project will develop new methods to predict liver cancer risk and outcomes using circulating samples rather than invasive biopsies. Our data shows that tissue and cells shed specific blebs into the circulation and these can contain unique information about the tissue of origin. We propose a series of experiments to show that these circulating samples are able to predict risk and outcomes with liver
Amplifying light emission with metal-fluorophore nanostructures for ultrasensitive biosensing. This proposal focuses on translating nanotechnology to ultrasensitive molecular monitoring for biomedicine. We will apply a new tool, amplified fluorophores to proteomics where they will provide an improved method for early detection and understanding of diseases through molecular fingerprints. The project will also generate an ultra-sensitive, rapid technology that can be used for personalized point ....Amplifying light emission with metal-fluorophore nanostructures for ultrasensitive biosensing. This proposal focuses on translating nanotechnology to ultrasensitive molecular monitoring for biomedicine. We will apply a new tool, amplified fluorophores to proteomics where they will provide an improved method for early detection and understanding of diseases through molecular fingerprints. The project will also generate an ultra-sensitive, rapid technology that can be used for personalized point-of-care diagnostics. The applications can include the detection of disease markers, pathogens or the determination of protein content in a clinical sample. These technologies will be applicable across a spectrum or of diseases all of which will benefit the broader community.Read moreRead less
Solving the problem of detecting small molecules in complex samples: A Label-Free Electrochemical Immuno-biosensor for drugs and pesticides. Biosensors are portable analytical devices which can be used by the general public without specialist training. The proposed research will develop a biosensor for the detection of small molecules such as pesticides, poisons and drugs; a class of analytes where there is currently no viable biosensor technology. The simple to use device will benefit the Aus ....Solving the problem of detecting small molecules in complex samples: A Label-Free Electrochemical Immuno-biosensor for drugs and pesticides. Biosensors are portable analytical devices which can be used by the general public without specialist training. The proposed research will develop a biosensor for the detection of small molecules such as pesticides, poisons and drugs; a class of analytes where there is currently no viable biosensor technology. The simple to use device will benefit the Australian community by providing technology which will allow rapid and inexpensive monitoring of water as well as biomedical diagnosis. The research will also benefit Australia via providing the training of scientists to establish the new generation of Australia's bionanotechnology industry. Read moreRead less
Biocompatible Ionic Liquids - Preserving Bioactive Structure and Function. A family of liquids recently discovered at Monash University has an ability to preserve bioactive molecules that represents a breakthrough in biotechnology. These new biocompatible ionic liquids will be investigated for applications in the treatment of diseases such as haemophilia. The ability of these liquids to stabilise a wide range of enzymes also opens up the potential of their use in a range of biosensors such as b ....Biocompatible Ionic Liquids - Preserving Bioactive Structure and Function. A family of liquids recently discovered at Monash University has an ability to preserve bioactive molecules that represents a breakthrough in biotechnology. These new biocompatible ionic liquids will be investigated for applications in the treatment of diseases such as haemophilia. The ability of these liquids to stabilise a wide range of enzymes also opens up the potential of their use in a range of biosensors such as blood glucose monitors for diabetes management. In collaborations with research groups worldwide, these materials will also be applied to the preservation of bioactivity in applications including cryopreservation of endangered species such as coral and in medical therapeutics. Read moreRead less